Show simple item record

dc.contributor.advisorLembani, Martina
dc.contributor.authorNgolele, Nkateko Lebogang
dc.date.accessioned2023-08-15T08:08:39Z
dc.date.available2023-08-15T08:08:39Z
dc.date.issued2023
dc.identifier.urihttp://hdl.handle.net/11394/10495
dc.description>Magister Scientiae - MScen_US
dc.description.abstractBackground: Drug-resistant tuberculosis is currently considered an ongoing public health crisis and a health security threat. Several strategies for the management of MDR/RR- TB have been explored including the use of repurposed drugs like linezolid, fluoroquinolones, and the addition of new TB-specific medications like bedaquiline and delamanid. Linezolid has been extensively studied in the treatment of drug-resistant tuberculosis. Although linezolid is an important option for drug-resistant tuberculosis management, its prolonged use has been associated with treatment-limiting side effects including peripheral neuropathy, optic neuritis, myelosuppression including severe anaemia and gastrointestinal toxicity.en_US
dc.language.isoenen_US
dc.publisherUniversity of the Western Capeen_US
dc.subjectLinezoliden_US
dc.subjectAdverse eventsen_US
dc.subjectDrug resistant tuberculosisen_US
dc.subjectSouth Africaen_US
dc.subjectHIV co-infecteden_US
dc.titleThe incidence of linezolid-associated side effects in MDR/RR-TB patients receiving routine care at a tertiary hospital in Johannesburg, South Africaen_US
dc.rights.holderUniversity of the Western Capeen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record